# Epigenetic pathology and therapy in Huntington's disease

> **NIH NIH R01** · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2022 · $408,497

## Abstract

The simple genetic cause of Huntington’s disease contrasts starkly with the vast number of pathways that are
affected by the mutation. Some of these pathway-level changes may persist even if the mutated allele of the
disease-causing gene (HTT) can be corrected through gene therapy or related methods. During the first granting
period, our analysis of HD models identified several potential therapeutic directions, including ones closely tied
to epigenetics (the transcriptional regulators NEUROD1, WNTand ELK-1), as well as pathways that interact with
epigenomic changes (energy metabolism and lipid biochemistry). Some of these effects were restricted to
particular cell types in the brain. We also found evidence that mutant HTT (mHTT) expression causes
neurodevelopmental impairments, changing the distribution of cell types in the brain. We and others have also
identified a significant number of genetic variants in the human population for which there is significant support
for an impact of that variant on HD age of onset (AOO).
In the current proposal, we examine the therapeutic potential of interventions based on these findings. We will
target these pathways in mice, measuring how interventions alter transcription, the epigenome, signaling and
metabolomics. A critical innovation is our use of single-cell and spatially resolved methods to examine how
responses to mHTT and therapeutics vary among different types of cells. Equally important, we will differentiate
specific cell types from induced-pluripotent stem cells (iPSC) in vitro to examine cell-type specific effects in
human cells. Using an approach based in systems biology we will look for common pathways that are affected
by the genetic AOO modifiers, the candidates from our prior grant period and leads from the literature. Our
approach is highly innovative, as it uses cutting edge experimental methods with single-cell and spatial resolution
to reveal aspects of HD that cannot be detected in homogenates. We also computationally integrate multi-omic
data (genomics, epigenomics, transcripts, proteins and metabolites) from the individual cells and brain regions
to uncover therapeutic pathways. The research is highly significant, as it seeks to guide therapeutic discovery
for an invariably fatal neurodegenerative disease. We expect that the impact of our work will extend beyond HD,
by providing a model for how to measure and model cell-type specific neurodegeneration to identify therapeutic
approaches.

## Key facts

- **NIH application ID:** 10411989
- **Project number:** 5R01NS089076-08
- **Recipient organization:** MASSACHUSETTS INSTITUTE OF TECHNOLOGY
- **Principal Investigator:** Ernest Fraenkel
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $408,497
- **Award type:** 5
- **Project period:** 2015-04-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10411989

## Citation

> US National Institutes of Health, RePORTER application 10411989, Epigenetic pathology and therapy in Huntington's disease (5R01NS089076-08). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10411989. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*